SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA Fundamental Analysis
SCHOTT Pharma AG & Co. KGaA (1SXP.F) shows moderate financial fundamentals with a PE ratio of 14.93, profit margin of 15.13%, and ROE of 17.12%. The company generates $1.0B in annual revenue with moderate year-over-year growth of 3.04%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 1SXP.F's fundamental strength across five key dimensions:
Efficiency Score
Weak1SXP.F struggles to generate sufficient returns from assets.
Valuation Score
Excellent1SXP.F trades at attractive valuation levels.
Growth Score
Weak1SXP.F faces weak or negative growth trends.
Financial Health Score
Excellent1SXP.F maintains a strong and stable balance sheet.
Profitability Score
Excellent1SXP.F achieves industry-leading margins.
Key Financial Metrics
Is 1SXP.F Expensive or Cheap?
P/E Ratio
1SXP.F trades at 14.93 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1SXP.F's PEG of 1.34 indicates fair valuation.
Price to Book
The market values SCHOTT Pharma AG & Co. KGaA at 2.42 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.30 times EBITDA. This is generally considered low.
How Well Does 1SXP.F Make Money?
Net Profit Margin
For every $100 in sales, SCHOTT Pharma AG & Co. KGaA keeps $15.13 as profit after all expenses.
Operating Margin
Core operations generate 17.59 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.12 in profit for every $100 of shareholder equity.
ROA
SCHOTT Pharma AG & Co. KGaA generates $9.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
SCHOTT Pharma AG & Co. KGaA produces operating cash flow of $158.94M, showing steady but balanced cash generation.
Free Cash Flow
SCHOTT Pharma AG & Co. KGaA generates weak or negative free cash flow of $11.90M, restricting financial flexibility.
FCF Per Share
Each share generates $0.08 in free cash annually.
FCF Yield
1SXP.F converts 0.53% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.93
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.34
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.26
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.58
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How 1SXP.F Stacks Against Its Sector Peers
| Metric | 1SXP.F Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.93 | 28.66 | Better (Cheaper) |
| ROE | 17.12% | 671.00% | Weak |
| Net Margin | 15.13% | -44168.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.33 | Strong (Low Leverage) |
| Current Ratio | 1.58 | 4.49 | Neutral |
| ROA | 9.26% | -17052.00% (disorted) | Weak |
1SXP.F outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews SCHOTT Pharma AG & Co. KGaA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
68.80%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
89.02%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
72.34%
Industry Style: Defensive, Growth, Innovation
High Growth